دورية
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
| العنوان: | Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study |
|---|---|
| المؤلفون: | Bar, Noffar, Mateos, Maria Victoria, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig C., Rodriguez Otero, Paula, Bermúdez, Maria Aranzazu, Martin, Thomas, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas Rodriguez, Cristina, Cerchione, Claudio, De La Rubia, Javier, Oriol, Albert, Waibel, Heidi, Besemer, Britta, Thompson, Ethan, Kiesel, Brian, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San-Miguel, Jesús, Costa, Luciano |
| المصدر: | Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2011-2011, 1p |
| مستخلص: | Introduction : |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2023-180013 |